Girerd X, Hanon O, Pannier B, Vaïsse B, Mourad J-J
Comité français de lutte contre l'hypertension artérielle (CFLHTA), 5, rue des Colonnes-Du-Trône, 75012 Paris, France.
Ann Cardiol Angeiol (Paris). 2013 Jun;62(3):210-4. doi: 10.1016/j.ancard.2013.04.011. Epub 2013 May 21.
To evaluate from studies conducted between 2002 and 2012, trends in the use of antihypertensive drugs in France.
French League Against Hypertension Survey (FLAHS) were conducted in a representative sample of subjects aged 35 and over living in France. A list including the names for all antihypertensive drugs marketed at the time of each survey made it possible to detail drug therapies employed. Data analysis has taken the patient as a unity. The data obtained in 2002, 2007 and 2012 are subject to this analysis.
In 2012, 30% of the French population aged 35 and older was treated with antihypertensive drugs (11.4 million), while 24% were treated in 2002 (8.2 million). On average, prescription of antihypertensive included 1.4 ± 0.7 pills in 2002, 1.5 ± 0.8 in 2007 and 1.8 ± 0.9 in 2012, which corresponds to a pharmacological monotherapy prescribed in 47% of subjects in 2012, a different percentage than in 2007 (46%) and 2002 (56%). Over the period, the percentage of prescriptions of diuretics (41% to 42%) and ACE inhibitors (24% to 23%) and beta-blockers (35% to 36%) is stable, but they are increasing with ARBs (23% to 47%) and calcium antagonists (24% to 34%). The prescriptions of fixed-dose combinations were also increased (19% to 30%). In 2012, fixed-dose combinations included a diuretic (79%), an ARB (65%), an ACEI (23%) and a calcium antagonist (20%). Blood pressure control estimated with home blood pressure monitoring increases from 38% in 2002 to 50% in 2007 and 2012.
Changes in the use of antihypertensive drugs in France between 2002 and 2012 led to the prescription of antihypertensive treatment with associations in the majority. ARBs or ACEI are present on 70% of prescriptions with diuretics combined in 80%. Extensive use of fixed-dose combinations with diuretics and ARA2 characterizes this period in which it was observed an increase in blood pressure control in France.
通过对2002年至2012年间开展的研究进行评估，了解法国抗高血压药物的使用趋势。
法国高血压防治联盟调查（FLAHS）针对居住在法国的35岁及以上具有代表性的人群样本展开。一份包含每次调查时市场上所有抗高血压药物名称的清单，使得详细列出所采用的药物治疗方案成为可能。数据分析以患者个体为单位。对2002年、2007年和2012年获得的数据进行此项分析。
2012年，法国35岁及以上人群中有30%（1140万）接受抗高血压药物治疗，而2002年为24%（820万）。平均而言，抗高血压药物的处方量在2002年为1.4±0.7片，2007年为1.5±0.8片，2012年为1.8±0.9片，这相当于2012年47%的受试者采用了药理单药治疗，这一比例与2007年（46%）和2002年（56%）不同。在此期间，利尿剂（41%至42%）、血管紧张素转换酶抑制剂（24%至23%）和β受体阻滞剂（35%至36%）的处方比例稳定，但血管紧张素Ⅱ受体拮抗剂（23%至47%）和钙拮抗剂（24%至34%）的处方量在增加。固定剂量复方制剂的处方量也有所增加（19%至30%）。2012年，固定剂量复方制剂中包含利尿剂的占79%，血管紧张素Ⅱ受体拮抗剂的占65%，血管紧张素转换酶抑制剂的占23%，钙拮抗剂的占20%。通过家庭血压监测评估的血压控制率从2002年的38%升至2007年和2012年的50%。
2002年至2012年间法国抗高血压药物使用情况的变化导致多数抗高血压治疗采用联合用药处方。血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂出现在70%的处方中，其中80%与利尿剂联用。含利尿剂和血管紧张素Ⅱ受体拮抗剂的固定剂量复方制剂的广泛使用是这一时期的特点，在此期间法国的血压控制率有所提高。
